Bronfman E.L. Rothschild L.P. cut its stake in Humana Inc (NYSE:HUM) by 6.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 526 shares of the insurance provider’s stock after selling 37 shares during the period. Bronfman E.L. Rothschild L.P.’s holdings in Humana were worth $151,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently modified their holdings of HUM. FMR LLC increased its holdings in Humana by 1.4% during the 3rd quarter. FMR LLC now owns 12,379,797 shares of the insurance provider’s stock valued at $4,190,809,000 after purchasing an additional 167,283 shares in the last quarter. BlackRock Inc. increased its holdings in Humana by 1.2% during the 3rd quarter. BlackRock Inc. now owns 12,311,736 shares of the insurance provider’s stock valued at $4,167,767,000 after purchasing an additional 140,731 shares in the last quarter. Vanguard Group Inc increased its holdings in Humana by 1.4% during the 3rd quarter. Vanguard Group Inc now owns 10,104,225 shares of the insurance provider’s stock valued at $3,420,482,000 after purchasing an additional 140,864 shares in the last quarter. Capital International Investors increased its holdings in Humana by 3,030.3% during the 3rd quarter. Capital International Investors now owns 8,217,296 shares of the insurance provider’s stock valued at $2,781,719,000 after purchasing an additional 7,954,786 shares in the last quarter. Finally, Renaissance Technologies LLC increased its holdings in Humana by 14.1% during the 3rd quarter. Renaissance Technologies LLC now owns 3,174,800 shares of the insurance provider’s stock valued at $1,074,733,000 after purchasing an additional 391,300 shares in the last quarter. 93.28% of the stock is owned by institutional investors and hedge funds.
In other news, insider Roy A. Beveridge sold 8,278 shares of the firm’s stock in a transaction on Tuesday, February 19th. The stock was sold at an average price of $307.16, for a total value of $2,542,670.48. Following the transaction, the insider now directly owns 12,409 shares in the company, valued at approximately $3,811,548.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Christopher H. Hunter sold 15,586 shares of the firm’s stock in a transaction on Monday, February 25th. The stock was sold at an average price of $305.24, for a total value of $4,757,470.64. Following the completion of the transaction, the insider now owns 28,100 shares in the company, valued at $8,577,244. The disclosure for this sale can be found here. 0.54% of the stock is currently owned by company insiders.
Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, February 6th. The insurance provider reported $2.65 EPS for the quarter, beating the Zacks’ consensus estimate of $2.53 by $0.12. The firm had revenue of $14.17 billion for the quarter, compared to analyst estimates of $14.04 billion. Humana had a return on equity of 19.64% and a net margin of 2.96%. The business’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same period last year, the company earned $2.06 EPS. Analysts forecast that Humana Inc will post 17.49 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Friday, March 29th will be given a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.79%. This is a positive change from Humana’s previous quarterly dividend of $0.50. The ex-dividend date is Thursday, March 28th. Humana’s dividend payout ratio (DPR) is presently 6.87%.
A number of equities research analysts recently weighed in on the company. Credit Suisse Group dropped their price target on Humana from $390.00 to $352.00 and set an “outperform” rating for the company in a report on Thursday, February 7th. Stephens assumed coverage on Humana in a report on Monday, January 14th. They set an “overweight” rating and a $336.00 price target for the company. Zacks Investment Research cut Humana from a “buy” rating to a “hold” rating in a report on Friday, February 8th. Cowen raised Humana from a “market perform” rating to an “outperform” rating and set a $275.02 price target for the company in a report on Friday, January 11th. Finally, Cantor Fitzgerald reaffirmed a “hold” rating and set a $325.00 price target on shares of Humana in a report on Wednesday, January 2nd. Five research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $355.06.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Further Reading: Cost of Equity
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.